Kindred Biosciences (Kindred Biosciences) Loans Receivable : $0.00 Mil (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences Loans Receivable?

Kindred Biosciences's Loans Receivable for the quarter that ended in Jun. 2021 was $0.00 Mil.

Kindred Biosciences Loans Receivable Historical Data

The historical data trend for Kindred Biosciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindred Biosciences Loans Receivable Chart

Kindred Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Loans Receivable

Get a 7-Day Free Trial

Kindred Biosciences Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Kindred Biosciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Kindred Biosciences Loans Receivable Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindred Biosciences (Kindred Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010

Website

https://www.kindredbio.com

Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.

Executives

Richard Chin	director, officer: Chief Executive Officer	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee	officer: Chief Financial Officer	C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken	director	C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery	director	C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof	officer: SVP of Regulatory Affairs	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley	officer: Chief Commercial Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker	officer: Chief Financial Officer	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010